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Figure 1. Patient risk status determined by cytogenetic and molecular studies of bone marrow aspirate. Presence of the following
abnormalities placed a patient in the appropriate risk status: Favorable; inv(16), t(16;16), t(8;21), t(15;17), normal cytogenetics with
NPM1(+) and FLT3-ITD(-), Intermediate; normal cytogenetics,+8, t(9;11), other non-defined, Poor; complex, monosomal karyotype, 5, 5q-, -7, 7q-, 11q23, inv(3), t(3;3), t(6;9), t(9;22), normal cytogenetics with FLT3-ITD(+)1.Percent of patients in each risk
stratification group were as following: favorable, 13%; intermediate, 45%; poor, 23%; not available (N/A), 19%. Patients who did not
have cytogenetic studies performed either did not receive further care or were put on hospice care, so the study was not needed.

Treatment Received for Elderly Patients with AML
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Figure 4. Frequency of FLT3-ITD mutation among the elderly AML patients whom have
normal karyotypes. Out of the 120 elderly patients treated at Lehigh Valley Health
Network from 2010-2014, 97 patients had cytogenetic studies performed. 41 patients had
normal cytogenetics and 17 patients had additional molecular studies performed. Of the
17 patients, 5 patients (29%) obtained the FLT-ITD mutation and 12 patients (71%) did
not.
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Figure 2. Treatment received for elderly patients with AML according to risk status. Percent of patients in each risk status that
received the following treatments. (Dark Green) supportive care: transfusion support, hydroxyurea, hospice (Dark Blue)
chemotherapy: single or combination 7+3 (standard-dose cytarabine with an anthracycline), MEC (mitoxantrone, etoposide, Ara-C),
Vidaza (5-azacytidine), and/or Dacogen (decitabine), (Light Blue) clinical trial, (Light Green) chemotherapy + other treatment
regiment, either stem cell transplant, clinical trial, or Mylotarg (gemtuzumab).
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• Treatments offered by LVHN were in accordance
with the NCCN guidelines and were similar across
risk status groups1.
• There was about a 13% survival rate, consistent
with the literature range2.
• There were no survivors within the poor risk group,
despite receiving the same treatments as patients
with more favorable cytogenetics. Clinical trials
should be encouraged for patients with poor risk
cytogenetics.
• Potential therapeutic benefit for patients with a
normal karyotype and FLT3-ITD mutation.
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• 137 cases of elderly AML seen by LVHN were
reviewed. 15 cases did not fit the classification of
AML and 2 transferred care. These cases were
excluded from our study, leaving 120 cases to be
reviewed.
• Age of diagnosis, cancer morphology, presence of
comorbidities, cytogenetic and molecular testing for
risk stratification, treatment received, and overall
survival were determined by reviewing all patient
transcripts including pathology reports.
• The National Comprehensive Cancer Network
Clinical Practice Guidelines in Oncology for Acute
Myeloid Leukemia Version 1.2016 was referenced
to compare treatment offered by LVHN to the
national standard1.
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• Acute myeloid leukemia (AML) is the most
common type of acute leukemia among adults and
causes the largest number of annual deaths from
leukemias in the United States1.
• Majority of AML patients are elderly, defined as age
60 and above, with a median age of diagnosis of
67 years and a 5-year survival range of 5-15%2.
• Advanced age is one of the major prognostic
factors in AML due to the increase in comorbidities
and a greater likelihood for unfavorable cytogenetic
abnormalities3.
• FLT3 gene encodes for a tyrosine kinase receptor
involved in hematopoiesis. Elderly patients have a
higher frequency for the FLT3-ITD mutation, which
is associated with an increased relapse risk and
shorter overall survival4.
• The goals of our study are to determine whether
treatments offered to elderly AML patients at LVHN
from 2010-14 were in accordance with the National
Comprehensive Cancer Network (NCCN)
Guidelines Version 1.2016 and to determine the
overall survival of elderly AML patients and
compare survival across risk groups.
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Figure 3. Survival of AML patients. A. Overall survival, 16 out of 120 patients survived (13%) and 104 expired (87%). B. Overall
survival by risk status as following: favorable; 50% alive 50% expired, intermediate; 15% alive 85% expired, poor; 0% alive
100% expired.
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